Loading...
Market
What will be the total number of Bavarian Nordic mpox vaccine doses administered in the UK by December 31, 2024?
2
Resolution / Starting Odds
Less than 50,000 • 25%
50,000 to 99,999 • 25%
100,000 to 150,000 • 25%
More than 150,000 • 25%
Public health records and announcements from the UK government
Story
WHO Approves Bavarian Nordic Mpox Vaccine as UK and Gavi Ramp Up Efforts with 500,000 Doses
Sep 18, 2024, 09:15 AM
The World Health Organization (WHO) has granted its first authorization for the use of a vaccine against mpox in adults, marking a significant step in combating the disease in Africa. The vaccine, developed by Bavarian Nordic, is the first to be approved by WHO for containing the spread of mpox in African countries. In response to the outbreak, the UK has ordered over 150,000 doses of the Bavarian Nordic mpox vaccine to enhance its preparedness against a new strain of the virus. Furthermore, the global vaccine alliance Gavi has announced plans to purchase 500,000 doses of the Bavarian Nordic mpox vaccine, allocating $50 million for this initiative to support African countries hardest hit by the outbreak. The WHO declared the mpox outbreak in several African countries a public health emergency of international concern in August.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 1 million • 25%
1 to 3 million • 25%
3 to 5 million • 25%
More than 5 million • 25%
Yes • 50%
No • 50%
Nigeria • 25%
Kenya • 25%
South Africa • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
Less than 1 million • 25%
1-5 million • 25%
5-10 million • 25%
More than 10 million • 25%
0-5 million doses • 25%
5.1-10 million doses • 25%
10.1-15 million doses • 25%
15.1+ million doses • 25%
Less than 30% • 25%
30% to 50% • 25%
50% to 70% • 25%
More than 70% • 25%